Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories’ filings are rich with science-heavy details—from FreeStyle Libre sales milestones to clinical trial results on cardiovascular stents—yet those disclosures are scattered across hundreds of pages. Locating segment margins, new product risks, or Abbott Laboratories insider trading Form 4 transactions can feel like a full-time job.
Stock Titan solves this by pairing real-time EDGAR feeds with AI-powered summaries that turn dense paragraphs into plain-English insights. Whether you’re checking an Abbott Laboratories quarterly earnings report 10-Q filing minutes after release or monitoring Abbott Laboratories Form 4 insider transactions real-time, our platform flags the numbers and footnotes that move markets. Investors searching for “Abbott Laboratories SEC filings explained simply” or “understanding Abbott Laboratories SEC documents with AI” land here because we answer those exact questions—instantly.
Here’s how each document can sharpen your view of ABT:
- 10-K annual report: See R&D spend by segment, global revenue mix, and get an Abbott Laboratories annual report 10-K simplified with AI call-outs.
- 10-Q quarterly report: Compare sequential growth, inventory trends, and access an Abbott Laboratories earnings report filing analysis within seconds.
- 8-K material events: Stay ahead of product recalls or leadership changes with Abbott Laboratories 8-K material events explained before markets react.
- Form 4: Track Abbott Laboratories executive stock transactions Form 4 to spot buying or selling signals.
- Proxy (DEF 14A): Review Abbott Laboratories proxy statement executive compensation without wading through boilerplate.
Every filing type—historical or just posted—arrives on Stock Titan with expert analysis, keyword search, and exportable data so you can focus on decisions, not document hunting.
Philip P. Boudreau, EVP and CFO of Abbott Laboratories (ABT), filed a Form 4 reporting insider sales dated 08/08/2025. The filing lists a sale transaction reported at a weighted average price of $134.551 and notes transaction prices in the range $134.551 to $134.58. The table shows 5,550 shares sold (denoted D) and a direct beneficial ownership following the reported transaction of 51,003 shares. It also reports an indirect balance of 361 shares in the Abbott Laboratories Stock Retirement Trust as of August 8, 2025.
The Form 4 is signed on behalf of Mr. Boudreau by an attorney-in-fact and dated 08/11/2025. The filing includes an explicit offer to provide detailed per-price sale breakdowns upon request and discloses the reporting person’s title and relationship to the issuer. No additional financial metrics, forward-looking statements, or explanations of purpose for the sale are provided in the filing.
Abbott Laboratories (ABT) filed a Form 144 proposing the sale of 5,550 shares of common stock. The notice states the shares have an aggregate market value of $746,758.27 and lists total outstanding shares of 1,740,459,014. The proposed sale is to be executed through UBS Financial Services on the NYSE with an approximate sale date of 08/08/2025.
The filing shows all 5,550 shares were acquired by the filer as vested restricted stock awards on 02/28/2022 (1,801 shares), 02/28/2023 (3,559 shares), and 02/29/2024 (190 shares). The form reports "Nothing to Report" for securities sold in the past three months and includes the standard signature representation about absence of undisclosed material adverse information.
FAQ
What is the current stock price of Abbott Labs (ABT)?
What is the market cap of Abbott Labs (ABT)?
